Latest stories on CGEN
Compugen Q3 Earnings Preview
Seeking Alpha50 · neutralearnings
Compugen to Participate in November Investor Conferences
StockTitan52 · neutralproduct/pr
CellectGen Advances Periodontal Diagnostics in Collaboration with Kemp Proteins and DCNDx
PR Newswire58 · neutralproduct/pr
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
StockTitan50 · neutralgeneral
Stifel reiterates Compugen stock rating on ovarian trial update
Investing.com Analyst Ratings56 · neutralanalyst
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
PR Newswire56 · neutralproduct/pr
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
Seeking Alpha56 · neutralproduct/pr
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
PR Newswire56 · neutralproduct/pr
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire55 · neutralgeneral
Compugen (CGEN) Q2 2026 Earnings Call Transcript
The Motley Fool56 · neutralearnings
Compugen: Better Runway Ahead Of MAIA
Seeking Alpha63 · neutralanalyst
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Compugen Q2 Earnings Call Highlights
Yahoo Finance58 · neutralearnings
Compugen Sets September 10, 2026 Annual Meeting, Details Board, Pay and Auditor Votes
TipRanks50 · neutralgeneral
Compugen GAAP EPS of -$0.07 beats by $0.01, revenue of $2.6M beats by $1.32M
Seeking Alpha63 · neutralearnings
Compugen Reports Second Quarter 2026 Results
PR Newswire56 · neutralearnings
Compugen Q2 2026 Earnings Preview
Seeking Alpha42 · neutralearnings
Compugen to Participate in BTIG Biotechnology Conference 2026
PR Newswire56 · neutralgeneral
Compugen to Participate in BTIG Biotechnology Conference 2026
StockTitan56 · neutralgeneral
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
PR Newswire50 · neutralearnings
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
PR Newswire56 · neutralproduct/pr
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Seeking Alpha56 · neutralproduct/pr
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 | CGEN Stock News
StockTitan63 · neutralproduct/pr
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
PR Newswire56 · neutralproduct/pr